Logo for Mineralys Therapeutics Inc

Mineralys Therapeutics Investor Relations Material

Latest events

Logo for Mineralys Therapeutics Inc

Q3 2024

Mineralys Therapeutics
Logo for Mineralys Therapeutics

Q3 2024

11 Nov, 2024
Logo for Mineralys Therapeutics

Status Update

30 Oct, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from Mineralys Therapeutics Inc

Access all reports
Mineralys Therapeutics Inc. (MLYS) is a clinical-stage biopharmaceutical company developing treatments for diseases associated with abnormally elevated aldosterone levels. The company's flagship product candidate, lorundrostat, is a highly selective aldosterone synthase inhibitor, currently under investigation for its potential in treating hypertension. The company is headquartered in Radnor, Pennsylvania, and its shares are listed on the Nasdaq.